PEOPLE ON THE MOVE
Presage Biosciences
Presage Biosciences has appointed Brad Margus to its board of directors.
Presage is an oncology company with its own in vivo assessment technology, CIVO, for side-by-side comparisons of the effect of drug combinations on patient tumours.
The technique avoids exposing patients to the toxicity of systemic dosing. Presage offers it as a service to other companies, as well as developing its own oncology portfolio.
“With CIV, Presage has the potential to change the way cancer drugs are selected, tested and targeted, creating innovative treatment options with higher probability of success,” said new director Margus. He added the company aims to improve the clinical success rate of cancer drugs from 10% to 50% over the next ten years.
Margus is the co-founder of life sciences companies Exigence Neurosciences, Genome Bridge, Perlegen Sciences, and Envoy Therapeutics.
